Will Therapeutics Announces CQDM-Backed Research Collaboration to Advance First Targeted Pharmacological Treatment for Anorexia Nervosa and Other Compulsive Disorders

CAD $3.5 million, three-year project will support development of brain-targeted small molecules designed to address the biology of habit and compulsion MONTRÉAL, June 30, 2026 /PRNewswire/ -- Will Therapeutics, an early-stage biotechnology company developing novel small-molecule medicines...